General Information of Drug (ID: DMNVKU6)

Drug Name
crisaborole Drug Info
Synonyms Crisaborole ointment 2%; PF-06930164
Indication
Disease Entry ICD 11 Status REF
Atopic dermatitis EA80 Approved [1]
Cross-matching ID
PubChem CID
44591583
ChEBI ID
CHEBI:134677
CAS Number
CAS 906673-24-3
TTD Drug ID
DMNVKU6
ACDINA Drug ID
D00968

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Phosphodiesterase 4 (PDE4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Apremilast DMTWS9E Psoriasis vulgaris EA90 Approved [2]
Oxtriphylline DMLHSE3 Cough MD12 Approved [3]
Roflumilast DMPGHY8 Asthma CA23 Approved [4]
Ibudilast DM4LSPN Castleman's disease 4B2Y Approved [5]
Arofylline DM84AD1 Chronic obstructive pulmonary disease CA22 Phase 3 [6]
ARQ-151 DML61S4 Atopic dermatitis EA80 Phase 3 [7]
SUN13834 DMPK34E Gram-positive bacterial infection 1B74-1G40 Phase 2 [8]
ONO-6126 DMRT28X Chronic obstructive pulmonary disease CA22 Phase 2 [6]
E6005 DM1S489 Atopic dermatitis EA80 Phase 2 [9]
IC-485 DMB1UYV Chronic obstructive pulmonary disease CA22 Phase 2 [6]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Phosphodiesterase 4 (PDE4) TTV5CGO NOUNIPROTAC Modulator [1]

References

1 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
2 Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets. 2007 Mar;6(1):17-26.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
5 Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond. Nat Rev Drug Discov. 2019 Oct;18(10):770-796.
6 Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
7 Trial of Roflumilast Cream for Chronic Plaque Psoriasis. N Engl J Med. 2020 Jul 16;383(3):229-239.
8 Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol. 1994 Jun 2;258(1-2):85-94.
9 Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model. J Pharmacol Exp Ther. 2013 Jul;346(1):105-12.